PB2038: LENALIDOMIDE OR BORTEZOMIB AS MAINTENANCE TREATMENT OVERCOMES INFERIOR IMPACT OF HIGH-RISK CYTOGENETIC ABNORMALITIES IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA IN CHINA. (23rd June 2022) - Zhuang, Z.; Tian, Y.; Shi, L.; Zou, D.; Feng, R.; Tian, W.-W.; Yu, H.; Dong, F.; Liao, A.; Ma, Y.; Liu, Q.; Liu, S.; et al.